---
provider: asta
model: Asta Scientific Corpus Retrieval
cached: false
start_time: '2026-05-26T23:12:23.747903'
end_time: '2026-05-26T23:12:28.774655'
duration_seconds: 5.03
template_file: templates/hypothesis_deep_research.md
template_variables:
  disease_name: Ovarian High-Grade Serous Carcinoma
  category: ''
  hypothesis_group_id: canonical_hrd_parp_synthetic_lethality_model
  hypothesis_label: Canonical HRD-PARP Synthetic Lethality Model
  hypothesis_status: CANONICAL
  hypothesis_yaml: "hypothesis_group_id: canonical_hrd_parp_synthetic_lethality_model\n\
    hypothesis_label: Canonical HRD-PARP Synthetic Lethality Model\nstatus: CANONICAL\n\
    description: HGSOC HRR or FA/BRCA pathway deficiency creates a tumor-specific\
    \ defect in high-fidelity\n  double-strand-break repair, converting PARP-inhibitor-induced\
    \ single-strand break accumulation and platinum-induced\n  interstrand crosslinks\
    \ into selectively lethal lesions. This is the canonical synthetic-lethal exploitation\n\
    \  that underpins maintenance olaparib benefit and is the disease-level instantiation\
    \ of the dna_repair_synthetic_lethality\n  module's canonical hypothesis.\nevidence:\n\
    - reference: PMID:33475295\n  supports: SUPPORT\n  evidence_source: OTHER\n  snippet:\
    \ PARP inhibition causes synthetic lethality in breast cancers associated with\
    \ germline BRCA1\n    and BRCA2 mutations and is routinely used in clinical practice\
    \ for metastatic breast cancer.\n  explanation: Review evidence directly supports\
    \ PARP-inhibitor synthetic lethality in BRCA-associated\n    tumors as the canonical\
    \ mechanism.\n- reference: PMID:36082969\n  supports: SUPPORT\n  evidence_source:\
    \ HUMAN_CLINICAL\n  snippet: At 7 years, 67.0% of olaparib patients versus 46.5%\
    \ of placebo patients were alive, and 45.3%\n    versus 20.6%, respectively, were\
    \ alive and had not received a first subsequent treatment\n  explanation: SOLO1\
    \ long-term survival benefit is the clinical embodiment of HRD-PARP synthetic\
    \ lethality\n    in HGSOC."
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    query_char_limit: 500
    paper_limit: 50
    snippet_limit: 20
    snippet_paper_limit: 50
    restrict_snippets_to_papers: false
    paper_fields: title,abstract,authors,year,url,venue,journal,tldr,publicationDate,citationCount,influentialCitationCount,externalIds
    publication_date_range: ''
    venues: ''
    inserted_before: ''
citation_count: 18
---

## Question

# Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** Ovarian High-Grade Serous Carcinoma
- **Category:**

## Target Hypothesis
- **Hypothesis ID:** canonical_hrd_parp_synthetic_lethality_model
- **Hypothesis Label:** Canonical HRD-PARP Synthetic Lethality Model
- **Status in KB:** CANONICAL

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: canonical_hrd_parp_synthetic_lethality_model
hypothesis_label: Canonical HRD-PARP Synthetic Lethality Model
status: CANONICAL
description: HGSOC HRR or FA/BRCA pathway deficiency creates a tumor-specific defect in high-fidelity
  double-strand-break repair, converting PARP-inhibitor-induced single-strand break accumulation and platinum-induced
  interstrand crosslinks into selectively lethal lesions. This is the canonical synthetic-lethal exploitation
  that underpins maintenance olaparib benefit and is the disease-level instantiation of the dna_repair_synthetic_lethality
  module's canonical hypothesis.
evidence:
- reference: PMID:33475295
  supports: SUPPORT
  evidence_source: OTHER
  snippet: PARP inhibition causes synthetic lethality in breast cancers associated with germline BRCA1
    and BRCA2 mutations and is routinely used in clinical practice for metastatic breast cancer.
  explanation: Review evidence directly supports PARP-inhibitor synthetic lethality in BRCA-associated
    tumors as the canonical mechanism.
- reference: PMID:36082969
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: At 7 years, 67.0% of olaparib patients versus 46.5% of placebo patients were alive, and 45.3%
    versus 20.6%, respectively, were alive and had not received a first subsequent treatment
  explanation: SOLO1 long-term survival benefit is the clinical embodiment of HRD-PARP synthetic lethality
    in HGSOC.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce artifact-friendly outputs such as an
evidence matrix, mechanistic diagram, knowledge-gap table, or comparison table.
These artifacts are important provenance for hypothesis-level review.


## Output

# Asta Literature Retrieval: Mechanistic Hypothesis Search You are evaluating a specific disease mechanism hypothesis for the Disorder Mechanisms...

This report is retrieval-only and is generated directly from Asta results.

- Papers retrieved: 18
- Snippets retrieved: 20

## Relevant Papers

### [1] Gathering Evidence of Mechanisms
- Authors: Veli-Pekka Parkkinen, Christian Wallmann, Michael Wilde, B. Clarke, P. Illari et al.
- Year: 2018
- Venue: Unknown venue
- URL: https://www.semanticscholar.org/paper/06480fd932fc88915a4efb4c894a5ae4ed98452d
- DOI: 10.1007/978-3-319-94610-8_5
- Citations: 1
- Summary: Key issues include increased precision concerning the nature of the hypothesis being examined, attention to differences between the study population and the target population of the evidence assessors, and being alert for masking mechanisms, which are other mechanisms which may mask the action of the mechanism being assessed.
- Evidence snippets:
  - Snippet 1 (score: 0.623)
    > General mechanistic claim for efficacy. In formulating the general mechanistic claim for efficacy, the following questions should be addressed:
    > • What is the relevant population?
    > • What is the intervention or exposure level?
    > • What is the outcome and how is it measured? General mechanistic claim for external validity. In determining the general mechanistic claim concerning external validity, the following questions should be addressed:
    > • What is the target population? What is the study population?
    > • What is the intervention or exposure level in the target?
    > • What is the outcome and how is it measured in the target?
    > • What is the intervention or exposure level in the study?
    > • What is the outcome and how is it measured in the study?
    > It may be that existing evidence from clinical studies together with already wellestablished mechanisms is enough to establish the general mechanistic claim. In other cases, the existing evidence fails to establish causality, and it is necessary to identify and evaluate mechanistic studies. To this end, this chapter presents the following five-step strategy for gathering evidence of mechanisms:
    > 1. Identify: Identify a number of specific mechanism hypotheses. 2. Formulate: For each specific mechanism hypothesis, formulate a number of review questions. 3. Search: Use these review questions to search the literature. 4. Refine: Identify the evidence most relevant to the mechanism hypothesis by refining the results of this search. 5. Present. Present the evidence relevant to the mechanism hypothesis. This strategy is intended to help overcome some of the practical difficulties with identifying evidence of mechanisms-difficulties which may prevent appraisers from considering all the relevant evidence. Once this evidence of mechanisms has been identified, it can then be evaluated alongside the existing evidence of correlation from clinical studies, as explained in Chaps. 6 and 7.
    > The overall approach of this chapter is illustrated in Fig. 5.1. The five steps outlined above are explained in detail in the following sections.
  - Snippet 2 (score: 0.588)
    > The overall approach to gathering evidence of mechanisms of action. Each proposed mechanism of action, or partial description of proposed mechanism of action, is a specific mechanism hypothesis. But note that a specific mechanism hypothesis need not be a complete description of a mechanism.
    > Example: Specific mechanism hypotheses for determining efficacy.
    > Aspirin prevents heart disease via cyclooxygenase (COX) inhibition, and the mechanisms that underlie this prevention are established. However, aspirin also seems to reduce the incidence of some cancers. Here, the mechanisms are much less well understood. As Chan et al. (2011) write: "the mechanism of aspirin's antineoplastic effect is less clear, with substantial evidence supporting both COX-dependent and COX-independent mechanisms. Moreover, data supporting the importance of COX-dependent mechanisms are not entirely consistent concerning the relative importance of the COX-1 and COX-2 isoforms in carcinogenesis". In this quotation, the general mechanistic claim is that aspirin exhibits an antineoplastic effect. There are also a couple of more specific mechanism hypotheses, for example, that this antineoplastic effect is mediated by COX-dependent mechanisms. Evidence relating to these more specific mechanism hypotheses provides a way to determine the status of the general mechanistic claim.
    > External validity. In order to evaluate the general mechanistic claim that there is a mechanism in the target population sufficiently similar to the mechanism responsible for the correlation observed in the study population, specific mechanism hypotheses need to pertain to the mechanism of action. It is important to consider the possibility that the mechanism in the target population may contain further component mechanisms that counteract the mechanism of action in the study population and affect the extent of the correlation between the putative cause and effect. So one needs to ask, are there any masking mechanisms in the target population?
    > Example: Specific mechanism hypotheses for determining external validity.
    > According to NICE guidelines, treatment for hypertension should differ depending on ethnicity (NICE 2011). Although ACE-inhibitors have proved beneficial for hypertension in many study populations, there remains the question of whether they are the optimal treatment in some distinct target population, such as African or Caribbean populations.
  - Snippet 3 (score: 0.584)
    > Although ACE-inhibitors have proved beneficial for hypertension in many study populations, there remains the question of whether they are the optimal treatment in some distinct target population, such as African or Caribbean populations. In this case, it is necessary to determine the status of the following general mechanistic claim: the relevant hypertensive mechanisms in the study populations are sufficiently similar to the mechanisms in African or Caribbean populations. This general mechanistic claim can be evaluated by evaluating a more specific mechanism hypothesis, namely that African and Caribbean populations have a lower renin state. As we shall see in Chap. 6, there is some good mechanistic evidence in favour of this specific mechanism hypothesis, and this undermines the general mechanistic claim. This is why, instead, calcium channel blockers are the recommended antihypertensive treatment in African and Caribbean populations (Clarke et al. 2014).
    > There are two main ways to identify a specific mechanism hypothesis. First, a specific mechanism hypothesis may be proposed on the basis of published studies from the clinical study literature. If a clinical study establishes a correlation between a putative cause and effect, and the suggestion is that this correlation is causal, then the authors of such a study usually identify at least one possible mechanism hypothesis of the following form: It is plausible that mechanism with features F links the putative cause and effect in the study population. The study may also point out possible masking mechanisms (Illari 2011). Given this, the discussion section of a published paper that reports the results of a clinical study is a good place to look in order to locate a specific mechanism hypothesis.

### [2] PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas
- Authors: C. Tung, S. Mok, Y. Tsang, Z. Zu, Huijuan Song et al.
- Year: 2009
- Venue: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
- URL: https://www.semanticscholar.org/paper/120fdba92f33c126e0e86008300cb927c4350a14
- DOI: 10.1038/modpathol.2009.92
- PMID: 19525924
- PMCID: 2736318
- Citations: 99
- Influential citations: 8
- Summary: The presence of PAX2 expression in normal ovarian epithelia but expression in fallopian tube fimbria and ciliated epithelial inclusions would suggest the potential development of tumors of low malignant potential and of low-grade ovarian serous carcinomas from secondary Müllerian structures.
- Evidence snippets:
  - Snippet 1 (score: 0.586)
    > Ovarian cancer, a leading cause of cancer deaths among women in the United States, is estimated to affect over 20,000 women each year, with over 15,000 dying of the disease.(1) Serous carcinoma, the major histologic subtype of ovarian cancer, represents about 87% of advanced-staged cases. (2) Currently, no uniform grading system exists despite the fact that histologic grade is a significant prognostic factor in women with epithelial ovarian carcinoma.(3) Malpica et al. proposed a 2-tiered grading system for ovarian serous carcinoma based on nuclear atypia and mitotic rate and classified tumors into low-grade versus high-grade.(4) Low-grade carcinomas and ovarian serous tumors of low malignant potential are often associated together in histologic and molecular studies and are rarely linked with high-grade ovarian carcinoma. (4,5) Differences in clinical behavior further support the distinction between the two grades. Low-grade carcinomas are typically characterized by a younger patient population with longer overall survival and increased platinum chemoresistance compared to high-grade carcinomas. (6) These variations in histologic and clinical behavior have led investigators to suggest that low-grade and highgrade ovarian serous carcinomas may develop along different pathways, and tumors of lowmalignant potential may exist on a continuum with low-grade ovarian serous carcinoma.
    > The precise etiology and pathogenesis of ovarian carcinoma remains elusive despite significant research. The cell of origin is still widely unknown and debated. The most common hypothesis is that ovarian carcinomas develop from the surface epithelium or postovulatory inclusion cysts in response to trauma or prolonged exposure to hormones or other chemokines. (7)(8)(9) However, growing evidence suggests other possible etiologies, including the tubal epithelium and distal endosalpinx. (10,11) Molecular and translational studies have suggested that differences in development pathways may contribute to the clinical, histologic, and genetic differences between low-grade and high-grade ovarian serous carcinomas

### [3] An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment
- Authors: T. Motohara, K. Masuda, M. Morotti, Yiyan Zheng, Salma El-Sahhar et al.
- Year: 2018
- Venue: Oncogene
- URL: https://www.semanticscholar.org/paper/94e8742c8e77f59c6a2648bfdf0d8a9c9c928d7b
- DOI: 10.1038/s41388-018-0637-x
- PMID: 30568223
- PMCID: 6755962
- Citations: 192
- Influential citations: 4
- Summary: The biological mechanisms that regulate the highly orchestrated crosstalk between ovarian cancer cells and various cancer-associated stromal cells in the metastatic tumor microenvironment with regard to the omentum are reviewed to provide further insights into the development of novel therapeutic approaches for patients with advanced ovarian cancer.
- Evidence snippets:
  - Snippet 1 (score: 0.552)
    > cell carcinoma, and mucinous carcinoma [10]. These cancer types are inherently diverse diseases that are characterized by differences in precursor lesions, molecular mechanisms of carcinogenesis, patterns of progression and metastasis, responses to chemotherapy, and clinical outcomes [11][12][13][14]. In the early twenty-first century, a series of morphological and molecular genetic studies led researchers to propose a dualistic model of ovarian carcinogenesis that divided ovarian cancer into two groups: type I and type II [15,16]. High-grade serous carcinoma, which is a prototypical type II tumor, is the most common and extremely aggressive subtype and contributes primarily to the poor prognosis of ovarian cancer patients [5,17,18]. Because of the high metastatic potential of high-grade serous carcinoma, a large proportion of patients are diagnosed at an advanced stage with multiple intraperitoneal disseminated tumors. Furthermore, a marked predilection for the adipose-rich omentum as the site of metastasis can be observed [4,5]. Considering that most ovarian cancer-related deaths are directly attributable to the development of metastatic disease, an in-depth understanding of the cellular and molecular aspects of ovarian cancer metastasis is crucial to overcome this life-threatening disease [19][20][21].
    > Over a century ago, the English surgeon Stephen Paget proposed the "seed and soil" hypothesis, which stated that the pattern of metastasis is not random and that the development of cancer metastasis depends on the crosstalk between particular cancer cells "the seeds" and a specific organ microenvironment "the soil" [22,23]. Since then, extensive efforts have been made to evaluate the reciprocal interactions between cancer cells and tumor microenvironments, which are heterogeneously composed of different cell types, including fibroblasts, endothelial cells, adipocytes, various bone marrow-derived cells, such as myeloidderived suppressor cells, mesenchymal stem cells (MSCs), and macrophages [24,25]. Researchers have shown that a host of strom

### [4] A Resident’s Perspective of Ovarian Cancer
- Authors: Christopher G. Smith
- Year: 2017
- Venue: Diagnostics
- URL: https://www.semanticscholar.org/paper/e7187ce9b848d3233d797ed025fd8984fdc4cd36
- DOI: 10.3390/diagnostics7020024
- PMID: 28448435
- PMCID: 5489944
- Citations: 15
- Influential citations: 3
- Summary: It is demonstrated that regular TVUS examinations can detect ovarian cancer at early stages, and that survival is increased in those women whose ovarian cancer was detected with screening and who undergo standard treatment.
- Evidence snippets:
  - Snippet 1 (score: 0.542)
    > Historically, these cells can either be those that line the surface of the ovary (epithelial) or those that originate from the ovary as non-epithelial cancers (embryonic or extra-embryonic (germ), hormone-producing, or structural cells [sex-cord stromal]) [4][5][6][7][8].In recent years, numerous reports have proposed a unified hypothesis about the origin of high-grade serous ovarian cancer, implicating the Fallopian tubes fimbria as the point of origin [9][10][11][12][13][14][15][16][17][18].In this hypothesis, invasive or serous tubal intraepithelial carcinoma (STIC) originating in the Fallopian fimbria is responsible for seeding the ovaries and peritoneal cavity with malignant cells [19].However, STIC is not present in many high-grade serous carcinomas [20].
    > Ovarian cancer generally affects older women, the average age being 63 [21].Ovarian cancer is the eleventh most common cause of cancer among women, with a lifetime risk of one in 70 to develop disease [22].It is also the leading cause of death from gynecological malignancy.Nearly two thirds of ovarian carcinomas are diagnosed with disease located outside of the pelvis and thereby impose the consequences of advanced stage disease.Overall, the five-year survival rate for women diagnosed with ovarian cancer is 46%.When ovarian cancer spreads to distant sites, five-year survival decreases to 28%, and decreases to nearly 16% with Stage 4 disease [1].

### [5] High grade serous ovarian carcinomas originate in the fallopian tube
- Authors: S. Labidi-Galy, E. Papp, Dorothy Hallberg, N. Niknafs, V. Adleff et al.
- Year: 2017
- Venue: Nature Communications
- URL: https://www.semanticscholar.org/paper/b491df3d0b6c859c6170c9c1a949e044cc7fce0e
- DOI: 10.1038/s41467-017-00962-1
- PMID: 29061967
- PMCID: 5653668
- Citations: 642
- Influential citations: 26
- Summary: Genetic aberrances in fallopian tube lesions, ovarian cancers, and metastases from HGSOC patients are analyzed and evolutionary analyses reveal that p53 signatures and STICs are precursors of ovarian carcinoma and identify a window of 7 years between development of a STIC and initiation of ovarian cancer, with metastases following rapidly thereafter.
- Evidence snippets:
  - Snippet 1 (score: 0.537)
    > High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian cancer and has a poor outcome. It has been proposed that fallopian tube cancers may be precursors of HGSOC but evolutionary evidence for this hypothesis has been limited. Here, we perform whole-exome sequence and copy number analyses of laser capture microdissected fallopian tube lesions (p53 signatures, serous tubal intraepithelial carcinomas (STICs), and fallopian tube carcinomas), ovarian cancers, and metastases from nine patients. The majority of tumor-specific alterations in ovarian cancers were present in STICs, including those affecting TP53, BRCA1, BRCA2 or PTEN. Evolutionary analyses reveal that p53 signatures and STICs are precursors of ovarian carcinoma and identify a window of 7 years between development of a STIC and initiation of ovarian carcinoma, with metastases following rapidly thereafter. Our results provide insights into the etiology of ovarian cancer and have implications for prevention, early detection and therapeutic intervention of this disease. It has previously been proposed that high-grade serous ovarian carcinoma (HGSOC) may originate from the fallopian tube. Here, the authors analyze genetic aberrances in fallopian tube lesions, ovarian cancers, and metastases from HGSOC patients and establish the evolutionary origins of HGSOC in the fallopian tube.

### [6] The fetal origins of adult disease: a narrative review of the epidemiological literature
- Authors: J. Skogen, S. Øverland
- Year: 2012
- Venue: JRSM Short Reports
- URL: https://www.semanticscholar.org/paper/b665dc20a1f7355f7c82e370d1e1fa3a0e2a7fce
- DOI: 10.1258/shorts.2012.012048
- PMID: 23301147
- PMCID: 3434434
- Citations: 102
- Influential citations: 4
- Summary: It is concluded that much of the research literature on the FOAD-hypothesis finds support for the hypothesis, and should be considered a major insight and constitutes a complement to a focus on genetic and more proximal factors (such as adult lifestyle) as causes of adult disease.
- Evidence snippets:
  - Snippet 1 (score: 0.535)
    > The FOAD-hypothesis has been praised as a paradigmatic shift from proximal factors to include distal factors as determinants of disease. 23 Some now argue that the empirical support for the link between an adverse intrauterine environment and later specific disease is so strong, that our focus should be to search for mechanisms. 24 thers criticize the hypothesis on a number of accounts, both methodologically and theoretically.
    > Susser and colleagues 25,26 has argued that the original hypothesis is too vaguely and broadly defined. According to them, stating that a fetus' nutritional status during gestation will influence the disease risk in adulthood, allows researchers to test a near unlimited matrix of potential nutritional measures and any later disease. Such a setting is prone to produce 'Type-I' errors. 27 Secondly, due to the general formulation of the original hypothesis it could not be readily falsified, which is crucial in scientific theory testing. 28 ather, as Paneth and Susser put it: 'example is piled on example, each somewhat consistent with hypothesis but none seriously testing it'. 26 These criticisms have been met to a certain degree by a further refinement of the basic hypothesis, 6 as well as a elaboration of the hypothesis in relation to specific diseases (such as the 'thrifty phenotype'). Additionally, there has been an increased focus on potential mechanisms underlying the proposed causal relationship, 6,11 including research based on animal models and intervention studies involving human subjects. 29 -31 Thus, through a more clear-cut formulation of the hypothesis (and disease-specific sub-hypotheses), development of a theoretical framework, identification of potential mechanisms and replication in animal models, some of the early criticism regarding the FOAD-hypothesis have been addressed. 27 he FOAD-hypothesis has also been criticized on account of how one should interpret the statistical association between anthropometric measures at birth, and outcomes in adulthood. As for any observed association, the relationship could be a result of chance, bias, confounders, or it may be a genuine causal effect. 32 any of the early criticisms of the observed association between anthropometric measures at birth and later disease concerned the lack of adjustment for important third variables. 25

### [7] New Insights into the Pathogenesis of Ovarian Cancer: Oxidative Stress
- Authors: G. Saed, R. T. Morris, N. Fletcher
- Year: 2018
- Venue: Ovarian Cancer - From Pathogenesis to Treatment
- URL: https://www.semanticscholar.org/paper/6c74938095716cbd46a218acde0b4b89bd78f7ae
- DOI: 10.5772/intechopen.73860
- Summary: This chapter provides the reader with up to date most relevant findings on the role of oxidative stress in the pathogenesis and prognosis of ovarian cancer, as well as a novel mechanism of apoptosis/survival in EOC cells.
- Evidence snippets:
  - Snippet 1 (score: 0.534)
    > [11][12][13]. The persistent generation of cellular reactive oxygen species (ROS) is a consequence of many factors including exposure to carcinogens, infection, inflammation, environmental toxicants, nutrients, and mitochondrial respiration [14][15][16][17].
    > The origin and causes of ovarian tumors remains under debate. Injury to surface epithelial ovarian cells due to repeated ovulation is thought to induce tumorigenesis in these cells and is known as the "incessant ovulation hypothesis." Additionally, hormonal stimulation of the surface epithelium of the ovary has been described to initiate tumorigenesis in surface epithelial cells and is known as the "gonadotropin hypothesis." Moreover, the fallopian tube, and not the ovary, has been suggested to be the origin for most epithelial ovarian cancer [2,18,19]. Nevertheless, many cases of ovarian cancer continue to be described as de novo.
    > Histopathologic, clinical and molecular genetic profiles were successfully utilized to clearly discriminate between type I and type II ovarian tumors [19]. Accordingly, type I ovarian tumors develop from benign precursor lesions that implant on the ovary and include clear cell, endometrioid, low-grade serous carcinomas, mucinous carcinomas and malignant Brenner tumors [19]. Type II ovarian tumors develop from intraepithelial carcinomas of the fallopian tube and can then spread to involve both the ovary as well as other sites, such as high-grade serous carcinomas which comprise morphologic and molecular subtypes [19]. Additionally, high-grade endometrioid, poorly differentiated ovarian cancers, and carcinosarcomas are also classified as type II tumors.
    > Attempts to identify specific genes in ovarian tumors to help in early detection of the disease and serve as targets for improved therapy had failed to identify reproducible prognostic indicators [2,[20][21][22]. Several oncogenic mutations and pathways have been identified in ovarian cancer. Specific inherited mutations in the BRCA1 and BRCA2 genes that produce tumor

### [8] A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection
- Authors: F. Langhauser, A. I. Casas, V. Dao, E. Guney, Jörg Menche et al.
- Year: 2018
- Venue: NPJ Systems Biology and Applications
- URL: https://www.semanticscholar.org/paper/44d6cd1d0dd2993b9a9f6b17e3f9705fb04892b8
- DOI: 10.1038/s41540-017-0039-7
- PMID: 29423274
- PMCID: 5799370
- Citations: 61
- Influential citations: 2
- Summary: It is shown that, based on this principle, a cardio-pulmonary drug can be surprisingly repurposed for a previously not recognised application as a direct neuroprotectant, and it is found that the cyclic GMP forming soluble guanylate cyclase becomes dysfunctional upon stroke but regains catalytic activity in the presence of specific activator compounds.
- Evidence snippets:
  - Snippet 1 (score: 0.531)
    > Drug discovery and development follows a relatively uniform path from mechanistic hypothesis, preclinical disease models to clinical validation. However, in recent years, a string of major drug developments have failed due to lack of efficacy. 1 One reason for this appears to reside in our current definitions of 'disease', i.e., mostly organ-based or by an apparent phenotype or symptom and not by an underlying mechanisms. However, without a validated pathomechanism no mechanism-based drugs can be developed and, therefore, rather surrogate parameters or risk factors are treated instead. Finding a rational approach towards mechanism-based disease definitions may therefore have a tremendous impact on drug discovery and medicine in general.
    > Using a data-driven approach, disease-disease networks (diseosome) have been constructed in which diseases are linked based on common molecular or regulatory mechanisms, 2 such as shared genetic associations, 2 protein interactions 3,4 or gene-disease interactions. 5 These diseasomes exhibit local clusters of diseases whose molecular relationships are well understood, but also unexpected clusters of surprisingly heterogeneous diseases. 3 Such clustering of disease phenotypes is likely due to underlying hidden common pathomechanisms. Importantly, these common mechanism clusters may provide previously unrecognized molecular definitions of these phenotypes and at the same time targets for mechanism-based drug discovery and repurposing.
    > Here we test the clinical validity of this approach by focusing on one cluster of highly prevalent combinations of vascular, neurological and metabolic disease phenotypes with high unmet medical need. Genetic evidence points to cGMP signaling as being part of its underlying pathomechanism. 5,6 We then inquire in a non-hypothesis-based manner using disease-disease networks based on common genetic origins, common protein interactions between disease genes, shared disease symptoms and disease co-morbidity for possible drug repurposing of cGMP modulators within this cluster.

### [9] Tumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing Theories
- Authors: Y. Man, A. Stojadinovic, J. Mason, I. Avital, A. Bilchik et al.
- Year: 2013
- Venue: Journal of Cancer
- URL: https://www.semanticscholar.org/paper/8cc82beaad33d7a1809ec739e2457ede0db158b4
- DOI: 10.7150/jca.5482
- PMID: 23386907
- PMCID: 3564249
- Citations: 180
- Influential citations: 2
- Summary: This mini-review presents several existing hypotheses and models that favor the promoting impact of tumor-infiltrating immune cells on tumor invasion and metastasis, and also analyzes their strength and weakness.
- Evidence snippets:
  - Snippet 1 (score: 0.530)
    > This hypothesis is based on both clinical observations of ovarian cancer patients and laboratory findings from studies of the synegeneic ID8 ovarian cancer model [98,99]. According to this hypothesis, "recruitment of Treg cells to the tumor supports disease progression through a dual mechanism: (1) the canonical subversion of antitumor immunity, and (2) through the establishment of a proangiogenic reprogramming of the tumor microenvironment". The authors of this hypothesis believe that the recruitment of regulatory T cells to the tumors are mediated primarily through the CCL28-CCR10 interaction [99].
    > The main strength of this hypothesis is that it is based on both clinical and laboratory data and that Treg-cell induced immune suppression has been well documented in multiple types of human cancer and diseases [100][101][102][103][104]. The main weakness of the hypothesis is that CCL28 is not a widely distributed molecule; consequently, the applicability of this hypothesis to other tumor types has yet to be established. In addition, this hypothesis fails to address the impact of immune cells on tumor stem cells, which are now believed to serve as the "seeds" for both invasive, metastatic, and recurrent cancer.

### [10] Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
- Authors: M. Köbel, S. Kalloger, Niki Boyd, S. McKinney, Erika Mehl et al.
- Year: 2008
- Venue: PLoS Medicine
- URL: https://www.semanticscholar.org/paper/eb0d584d28493e3219c8618f32f90ec6d43d04db
- DOI: 10.1371/journal.pmed.0050232
- PMID: 19053170
- PMCID: 2592352
- Citations: 846
- Influential citations: 24
- Summary: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses.
- Evidence snippets:
  - Snippet 1 (score: 0.524)
    > Ovarian carcinoma is a heterogeneous disease. On the basis of histopathological examination, pathologists classify ovarian carcinoma into serous, clear cell, endometrioid, and mucinous subtypes. Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4]. These subtypes differ dramatically in frequency, when early stage carcinomas (where the majority are nonserous carcinomas [5]) and advanced stage carcinomas (which are predominantly of serous subtype [6]) are compared.
    > Oncologists have noted that subtypes respond differently to chemotherapy. The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8]. Therefore, the National Cancer Institute (NCI) State of Science meeting recently singled out clear cell carcinoma as a candidate for clinical trials to identify more active therapy than what is currently available [9]. Although these data suggest substantial differences between subtypes, ovarian carcinoma is typically approached as a monolithic entity by researchers and clinicians. This practice impedes progress in understanding the biology or improving the management of the less common ovarian carcinoma subtypes.
    > We hypothesized that correlations between biomarker expression and stage at diagnosis or prognosis would reflect subtype variation in biomarker expression. To test this hypothesis we correlated protein expression rates of a panel of 21 candidate biomarkers with stage at diagnosis and disease-specific survival (DSS) in a large cohort of ovarian carcinomas and also analyzed these associations within ovarian carcinoma subtypes.

### [11] Recent Progress in the Diagnosis and Treatment of Ovarian Cancer
- Authors: D. Jelovac, D. K. Armstrong
- Year: 2011
- Venue: CA: a cancer journal for clinicians
- URL: https://www.semanticscholar.org/paper/96bac6c0748ab090fe304e3578072cf81bf6998d
- DOI: 10.3322/caac.20113
- PMID: 21521830
- PMCID: 3576854
- Citations: 788
- Influential citations: 32
- Summary: New targeted biologic agents, particularly those involved with the vascular endothelial growth factor pathway and those targeting the poly (ADP‐ribose) polymerase (PARP) enzyme, hold great promise for improving the outcome of ovarian cancer.
- Evidence snippets:
  - Snippet 1 (score: 0.520)
    > Ovarian cancer is heterogeneous disease, and it contains several histological subtypes. EOC accounts for over 90% of primary ovarian tumors and can be classified into distinct morphologic categories: serous, mucinous, endometrioid, clear cell, transitional cell (Brenner tumors), mixed, and undifferentiated type (Table 3).
    > Papillary serous histology accounts for 75% of ovarian cancers, and its histological pattern simulates the lining of the fallopian tube. High-grade, poorly differentiated tumors are the majority and are macroscopically indistinguishable from other epithelial tumors. This histologic variant is often associated with concentric rings of calcification known as psammoma bodies. Although no universal grading schema exists for ovarian serous carcinoma, a 2-tiered system (low-grade vs high-grade) has received increasing acceptance. 35,36 ][39] Studies aimed at identifying a precursor lesion within the ovary have been largely unsuccessful. Based on the observation of a high rate of tubal intraepithelial changes (TICs) in high-risk women undergoing RRSO, it has been hypothesized that many apparent ovarian or primary peritoneal carcinomas may be of fallopian tube origin. Recent studies have documented that up to 59% of high-grade pelvic (nonuterine) serous carcinomas are associated with serous TICs. This is consistent with the hypothesis that the fallopian tube is the source of a majority of these tumors. 40 2][43] Low-grade serous carcinomas and LMP serous tumors are characterized by a young age at diagnosis and a prolonged natural history. 39 The clinical behavior of LMP tumors that recur as low-grade invasive serous carcinomas appears similar to that of newly diagnosed low-grade serous carcinomas. 37 ther studies have shown that LMP tumors often coexist with low-grade serous carcinomas, and when they recur, frequently do so as low-grade serous carcinomas. 44,45

### [12] DeepEvidence: Empowering Biomedical Discovery with Deep Knowledge Graph Research
- Authors: Zifeng Wang, Zheng Chen, Ziwei Yang, Xuan Wang, Qiao Jin et al.
- Year: 2025
- Venue: ArXiv
- URL: https://www.semanticscholar.org/paper/f06a59cb27b36766098ecb235c9ada048e145ed0
- DOI: 10.48550/arXiv.2601.11560
- Citations: 2
- Summary: DeepEvidence is introduced, an AI-agent framework designed to perform Deep Research across various heterogeneous biomedical KGs, and demonstrates substantial gains in systematic exploration and evidence synthesis.
- Evidence snippets:
  - Snippet 1 (score: 0.517)
    > Edges represent a controlled set of mechanistic membership association and evidence level relations, and every node and relation is grounded with explicit provenance from primary literature or curated knowledge graphs. Rather than encoding context as free text, the agent attaches short factual observations to entities, capturing experimental setting methodology and quantitative or mechanistic outcomes. During reasoning, the agent queries the existing graph before adding new content, merges near duplicates, updates observations instead of creating redundant nodes, and records conflicting findings with separate evidence links. We add the prompt in Supplementary Note A.4 to the agent's system prompt as additional guidance. This tight coupling between the agent and the evidence graph enables iterative hypothesis refinement, evidence aggregation, and transparent traceability, ensuring that conclusions are derived from an explicit, structured, and auditable body of biomedical evidence.
    > To facilitate cross-knowledge-base research and entity bridging, we implemented unified modality-wise search tools that aggregate information from multiple authoritative sources through a single interface. For instance, the unified gene search tool queries BioThings (MyGene.info), KEGG, and Open Targets simultaneously, returning consolidated results with cross-database identifiers. Similar unified tools exist for diseases, drugs, compounds, targets, pathways, and variants. Beyond entity lookup, we integrated relation-based search capabilities via the PubTator3 API, enabling agents to discover entities linked through specific semantic relationships such as TREAT, CAUSE, INTERACT, INHIBIT, and ASSOCIATE. This allows agents to traverse from diseases to candidate drugs, from genes to associated phenotypes, or from chemicals to their biological targets, supporting the depth-first reasoning patterns essential for mechanistic hypothesis generation. Together, these unified search and relation tools provide the knowledge infrastructure that enables research agents to bridge heterogeneous knowledge graphs and synthesize evidence across multiple biomedical domains.

### [13] RareAgent: Self-Evolving Reasoning for Drug Repurposing in Rare Diseases
- Authors: Lang Qin, Z. Gan, Xu Cao, Pengcheng Jiang, Yankai Jiang et al.
- Year: 2025
- Venue: ArXiv
- URL: https://www.semanticscholar.org/paper/ad0dc7cd9de3e46fb22cc025706d54dfe58331a0
- DOI: 10.48550/arXiv.2510.05764
- Summary: RareAgent is presented, a self-evolving multi-agent system that reframes this task from passive pattern recognition to active evidence-seeking reasoning, and improves the indication AUPRC by 18.1% over reasoning baselines and provides a transparent reasoning chain consistent with clinical evidence.
- Evidence snippets:
  - Snippet 1 (score: 0.515)
    > RareAgent operationalizes the scientific discovery process using a team of four AI agents with specialized roles, who collaborate on a shared whiteboard by constructing T-EGraph.
    > • Principal Investigator (PI): The strategic orchestrator. The PI does not directly manipulate evidence but sets research goals, evaluates the state of the T-EGraph, identifies knowledge gaps, issues directives to other agents, and is responsible for self-evolutionary learning loops.
    > • Explorer: The hypothesis generator. The Explorer initiates the investigation by querying the external KG using GNN to propose an initial set of plausible drug-disease hypotheses.
    > • Proponent: The constructive advocate. The Proponent's goal is to build a coherent, mechanistic case for a given hypothesis. It searches for and adds supporting evidence to the T-EGraph, aiming to form complete causal chains (e.g., Drug → Target → Pathway → Phenotype).
    > • Skeptic: The adversarial challenger. The Skeptic's role is to challenge the current hypothesis by finding counter-evidence, identifying risks, and exposing logical fallacies. It adds refuting evidence, such as off-target effects or safety concerns, to the T-EGraph.
    > The overall workflow proceeds in three phases: (1) Hypothesis Generation, where the Explorer seeds the investigation;
    > (2) Iterative Refinement, an autonomous adversarial debate where the Proponent and Skeptic build upon the T-EGraph under the PI's guidance; and (3) Self-Evolution, where the PI analyzes completed investigations to refine agent policies and distill reusable knowledge. All four agents are realized as LLM modules with role-specific policies, and the backbone is swappable and orthogonal to our contributions.

### [14] Learning from our GWAS mistakes: from experimental design to scientific method
- Authors: Christophe Gerard Lambert, L. Black
- Year: 2012
- Venue: Biostatistics (Oxford, England)
- URL: https://www.semanticscholar.org/paper/7c92a4bffd527e9275e5dbc57e2037bc07fa93f9
- DOI: 10.1093/biostatistics/kxr055
- PMID: 22285994
- PMCID: 3297828
- Citations: 60
- Influential citations: 1
- Summary: In an era of large-scale biological research, questions are asked about the role of statistical analyses in advancing coherent theories of diseases and their mechanisms and for renewed appreciation of falsifiable hypotheses so that the authors can learn more from their best mistakes.
- Evidence snippets:
  - Snippet 1 (score: 0.510)
    > Collecting samples without specifying preliminary hypotheses leads to a frame of mind in which genetic assays are run without an experimental design that accounts explicitly for the hypotheses to be tested-in other words, not taking steps to randomize and so prevent biases in data. As with many large biological data collection efforts, GWAS are premised on an overarching hypothesis that a disease has a genetic cause, rather than many more granular hypotheses designed to challenge a causal theory of how a disease manifests. A GWAS might test a million null hypotheses that case-control status and a given genomic SNP are statistically independent over the population sample. The experiment to falsify these null hypotheses is an automated search for indications of association between genetic variants and disease status.
    > In the traditional scientific method, a hypothesis is a proposed explanation for a phenomenon, but scientists use the hypothesis to deduce additional predicted effects which, if observed, can corroborate the hypothesis but not prove it and, if not observed as predicted, can falsify the hypothesis. A single observation can falsify a traditional scientific hypothesis.
    > Such a hypothesis might describe a force or property common to all members of a population. A hypothesis of this sort must make universal claims in order to produce repeatable experiments; then a hypothesis tested by experimenting on a member of the population could be refuted for the entire population. If we abstract a hypothesis-forming process this way-"I have observed property X in a number of instances of A; I hypothesize that all other instances of A will have property X"-then the underlying premise is "All A's are effectively identical." If all A's are effectively identical, then we should accept that a corroborated or refuted hypothesis can inform us about the universe of A's. If A's are billiard balls, and we are looking at properties of how they transfer momentum on a billiard table, we would expect all instances of these A's to have the same properties.

### [15] An Application of Fuzzy Prototypes to the Diagnosis and Treatment of Fuzzy Diseases
- Authors: Rubén Romero-Córdoba, J. Olivas, F. P. Romero, Francisco Alonso-Gómez, J. Serrano-Guerrero
- Year: 2017
- Venue: International Journal of Intelligent Systems
- URL: https://www.semanticscholar.org/paper/36623f163659f9e4d1cf968252e10e36faa19676
- DOI: 10.1002/int.21836
- Citations: 20
- Influential citations: 1
- Summary: A reasoning method that uses theories about conceptual categorization from the psychology, pattern recognition, and Zadeh's prototypes has been designed and satisfactory results in the evaluation of patients were obtained.
- Evidence snippets:
  - Snippet 1 (score: 0.506)
    > Medical reasoning, as well as some kinds of scientific and technical reasoning, follows a logic of conjectures and refutations; that is, the physician from his encounter with the patient starts with different hypothesis which can be verified, or on the contrary, be refuted. If the hypothesis is refuted by experimental facts, it is subsequently replaced by other hypotheses that are better adapted to the facts. Thus, for each disease you can have, on the one hand, a degree of confirmation (i.e., the degree to which the evidence supports the hypothesis under consideration) and, on the other hand, a degree of refutation (i.e., the degree to the facts refute the hypothesis). The result of combining these two factors is the degree of credibility of this hypothesis. Therefore, each disease being considered by the system includes a set of facts that confirm or falsify. The logic model to present the factors confirmation, falsification, and credibility is based on fuzzy techniques, in extensions of the theory of prototypes of Zadeh. 8 ccording to the prototype resemblance theory of disease, 29 the nosological class that comprises such fuzzy human conditions as diseases cannot be based on and represented by, a classical, reductively definable concept of disease. Nevertheless, the class of diseases can be defined as an irreducible category that is constituted by some prototypes to which the remaining members of the category, the diseases, are similar to different extents. It is possible to consider that ideal types prototypically describe a disease, but in fact only approximate the ideal to a degree. Some kinds of diseases show some kinds of uncertainty or vagueness associated with the fulfillment of this ideal. Therefore, to develop this theory it is essential to measure the similarity between a member of a category and its prototype.
    > Fuzzy deformable prototypes (from now on FDPs) can provide an adequate formal framework for working with this idea.

### [16] Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis
- Authors: Keren Levanon, V. Ng, H. Piao, Yi Zhang, Martin C. Chang et al.
- Year: 2009
- Venue: Oncogene
- URL: https://www.semanticscholar.org/paper/a30e02ca02a8859a9ed7f4650aeae4d6b1693fcf
- DOI: 10.1038/onc.2009.402
- PMID: 19935705
- PMCID: 2829112
- Citations: 224
- Influential citations: 4
- Summary: The development of a novel ex vivo primary human FT epithelium culture system that faithfully recapitulates the in vivo epithelia is reported, as shown by morphological, ultrastructural and immunophenotypic analyses.
- Evidence snippets:
  - Snippet 1 (score: 0.502)
    > Epithelial ovarian cancer (EOC) is a leading cause of mortality in developed countries, with an incidence of about 190,000 new cases diagnosed annually worldwide, and 114,000 fatalities (Jemal et al., 2008). EOCs are generally subclassified into two types based on biological behavior and histology: low-grade tumors (also known as type I tumors), which typically present at an earlier stage and have an indolent natural history, and the high-grade or type II tumors, which typically have a more disseminated and aggressive behavior (Landen et al., 2008). Serous ovarian carcinoma (SOC) is a type II tumor and the most aggressive and most prevalent histological subtype of this disease (Cannistra, 2004). The poor prognosis of SOC is a direct consequence of advanced stage disease in a majority of newly diagnosed patients, and the eventual development of resistance to currently available chemotherapy.
    > Until recently, the ovarian surface epithelium (OSE) was considered the principal cell-oforigin for both type I and type II ovarian tumors. However, models depicting the transformation of the OSE have not been consistently corroborated by pathologic observations of transitions from OSE to malignancy. Recent studies raise a compelling hypothesis that the fallopian tube (FT) may harbor a cell-of-origin, the FT secretory epithelial cell (FTSEC), for serous tumors of the ovary and peritoneum (Jarboe et al., 2008). Evidence that supports this hypothesis includes: 1) 5-10% of BRCA+ women undergoing prophylactic salpingoophorectomy will have an early lesion, termed serous tubal intraepithelial carcinoma (STIC) and approximately 80% of these early cancers are found in the distal (fimbriated) end of the FT; 2) >50% of women with stage III/IV pelvic serous cancer also have a neoplastic lesion in their FT mucosa; 3) identical TP53 mutations have been identified in early FT neoplasia and the corresponding SOC (Kindelberger et al., 2007); 4) non-neoplastic

### [17] KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas
- Authors: M. T. Rahman, K. Nakayama, Munmun Rahman, H. Katagiri, A. Katagiri et al.
- Year: 2013
- Venue: International Journal of Molecular Sciences
- URL: https://www.semanticscholar.org/paper/b70c68e39f0258ef0a2cc08056fd4d14e13be01e
- DOI: 10.3390/ijms140713748
- PMID: 23820584
- PMCID: 3742215
- Citations: 30
- Influential citations: 1
- Summary: It is indicated that KRAS/MAPK1 amplification is critical for the growth of a subset of type II ovarian carcinomas and RAS/RAF/MEK/ERK pathway-targeted therapy may benefit selected patients with type Two ovarian carcinoma harboring KRAS or MAPK1 amplifications.
- Evidence snippets:
  - Snippet 1 (score: 0.499)
    > They are aggressive, present at advanced stages, and have a very high frequency of TP53 mutations, but rarely harbor the mutations detected in type I tumors [5].
    > Recent genome-wide analysis by TCGA, single nucleotide polymorphism arrays identified KRAS and MAPK1 as two of the most frequently amplified genes in high-grade serous ovarian carcinomas with the prototypic type in type II ovarian carcinomas [6]. Gene amplification represents one of the molecular genetic hallmarks of human cancer. Elucidating the molecular mechanisms of how amplified genes initiate and maintain malignant phenotypes and propel tumor progression is fundamental to understanding the molecular etiology of human cancer and its therapeutic implications. Gene amplification is an important mechanism that allows cancer cells to increase expression of driver genes, such as oncogenes, that are involved in growth regulation and genes responsible for drug resistance. Therefore, detection of gene amplification in tumors may be of diagnostic, prognostic, and/or therapeutic relevance for patient management.
    > Based on the above findings, we hypothesized that KRAS or MAPK1 amplification may play an important role in type II ovarian carcinoma progression and that amplification may correlate more strongly with clinical parameters. Furthermore, type II ovarian carcinomas with KRAS or MAPK1 amplification may be sensitive to a potential targeted therapeutic agent. To test this hypothesis, we undertook the current study to assess gene copy numbers of KRAS or MAPK1 and to evaluate any prognostic significance in patients with type II ovarian carcinoma. In addition, we compared phenotypes in cultured type II ovarian carcinoma cell lines with various KRAS or MAPK1 copy numbers after treatment using a selective MEK inhibitor.

### [18] The Rise of Hypothesis-Driven Artificial Intelligence in Oncology
- Authors: Zilin Xianyu, Cristina Correia, C. Ung, Shizhen Zhu, D. Billadeau et al.
- Year: 2024
- Venue: Cancers
- URL: https://www.semanticscholar.org/paper/f05721d59597ea5471ac85617fda99b4e73fb936
- DOI: 10.3390/cancers16040822
- PMID: 38398213
- PMCID: 10886811
- Citations: 17
- Summary: Hobbit-driven AI holds great promise in the discovery of new mechanistic and functional insights that explain the complexity of cancer etiology and potentially chart a new roadmap to improve treatment regimens for individual patients.
- Evidence snippets:
  - Snippet 1 (score: 0.498)
    > Despite their wide area of application in cancer research, hypothesis-driven AI tools show several areas for improvement. While some models such as OncoNPC have shown efficacy, there is a need to generalize these models across different patient populations and cancer types. However, since these models were developed based on disease-specific domain knowledge, this might inadvertently limit their utility in other disease contexts. Utilizing domain knowledge agnostic to a specific disease type while retaining the flexibility to adapt to a specific biological context can enhance the generalizability of a hypothesis-driven AI tool to broader disease types. Moreover, as the structure and dimensionality of data become more complex by including distinct biological layers such as genetics and environmental, researchers face greater challenges in formulating hypotheses that can effectively manage different levels of data attributes, and this demands further abstract reasoning from researchers. Additionally, the selection of which knowledge domain to integrate into algorithmic design remains subjective and varies among researchers.
    > Figure 4 summarizes the new ingredients needed for designing hypothesis-driven AI algorithms and illustrates how these can be utilized to unearth hidden gems embedded within the data to help better inform clinical decisions. Below we provide some open questions and food for thought that we think could inspire the development of hypothesisdriven AI in the near future.

## Notes

- This provider combines `search_papers_by_relevance` with `snippet_search`.
- No synthesis or second-stage model call is performed.
